Tag: Matthew Huber

Innovation in oncology drug development is driving more efficient and effective development of new cancer treatments. This innovation is providing cancer patients unprecedented access to new therapies. Dr Brian Huber, Vice President of Therapeutic Areas, Drug Development and Consulting at ICON and Matthew Huber, a scientist in the emerging biotechnology sector focused on developing innovative oncology medicines, have conducted a […]

Read More… from Innovation in oncology drug development: A focus on patient benefits